Disease and Treatment-Specific Complications of Behçet Syndrome.

IF 5.7 2区 医学 Q1 RHEUMATOLOGY Current Rheumatology Reports Pub Date : 2024-01-01 Epub Date: 2023-11-23 DOI:10.1007/s11926-023-01124-7
Sinem Nihal Esatoglu, Yesim Ozguler, Gulen Hatemi
{"title":"Disease and Treatment-Specific Complications of Behçet Syndrome.","authors":"Sinem Nihal Esatoglu, Yesim Ozguler, Gulen Hatemi","doi":"10.1007/s11926-023-01124-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>We aimed to highlight disease-related and treatment-related complications of Behçet syndrome (BS) based on previous and recent studies and our own experience.</p><p><strong>Recent findings: </strong>The Behçet's Disease Overall Damage Index is a newly developed instrument to assess damage in BS. Validation studies showed that damage is already present in some patients at diagnosis and continues to progress during the follow-up, mainly related to treatment complications. Nervous system and eye involvement are important causes of long-term disability. Cyclophosphamide seems to be associated with infertility and an increased risk of malignancies among BS patients, prompting the consideration of shortening the treatment duration. Flares in mucocutaneous manifestations have been reported with tocilizumab, and de novo BS manifestations with secukinumab therapy. Earlier diagnosis and treatment are essential to prevent disease-related damage in BS. Treatment-related complications seem to be the leading cause of damage during the disease course.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"1-11"},"PeriodicalIF":5.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-023-01124-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: We aimed to highlight disease-related and treatment-related complications of Behçet syndrome (BS) based on previous and recent studies and our own experience.

Recent findings: The Behçet's Disease Overall Damage Index is a newly developed instrument to assess damage in BS. Validation studies showed that damage is already present in some patients at diagnosis and continues to progress during the follow-up, mainly related to treatment complications. Nervous system and eye involvement are important causes of long-term disability. Cyclophosphamide seems to be associated with infertility and an increased risk of malignancies among BS patients, prompting the consideration of shortening the treatment duration. Flares in mucocutaneous manifestations have been reported with tocilizumab, and de novo BS manifestations with secukinumab therapy. Earlier diagnosis and treatment are essential to prevent disease-related damage in BS. Treatment-related complications seem to be the leading cause of damage during the disease course.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
behet综合征的疾病和治疗特异性并发症。
回顾目的:我们旨在根据以往和最近的研究以及我们自己的经验,强调behaperet综合征(BS)的疾病相关和治疗相关并发症。最近发现:behet病总体损害指数是一种新开发的评估BS损害的工具。验证研究表明,一些患者在诊断时已经出现损伤,并在随访期间继续进展,主要与治疗并发症有关。神经系统和眼睛受累是导致长期残疾的重要原因。环磷酰胺似乎与BS患者的不孕症和恶性肿瘤风险增加有关,促使人们考虑缩短治疗时间。有报道称,托珠单抗治疗后出现粘膜皮肤症状,而secukinumab治疗后出现BS新症状。早期诊断和治疗对于预防BS的疾病相关损害至关重要。治疗相关的并发症似乎是疾病过程中损害的主要原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
41
期刊介绍: This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.
期刊最新文献
How to Distinguish Non-Inflammatory from Inflammatory Pain in RA? Telemedicine for the Care of Patients with Idiopathic Inflammatory Myopathies: Experience, Insights and Future Directions from the International Myositis Assessment and Clinical Studies Telemedicine Scientific Interest Group. Treatment of Reactive Arthritis with Biological Agents. Recent Updates on the Pathogenesis of Inflammatory Myopathies. Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1